Hansa Biopharma AB (OSTO:HNSA)
kr 45.9 -2.6 (-5.36%) Market Cap: 3.00 Bil Enterprise Value: 3.41 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 73/100

Q2 2019 Hansa Biopharma AB Earnings Call Transcript

Jul 18, 2019 / 11:00AM GMT
Release Date Price: kr172.9
Operator

Ladies and gentlemen, welcome to the Hansa Biopharma Q2 report for 2019. Today, I am pleased to present Søren Tulstrup, President and CEO. (Operator Instructions). Søren, please begin.

SÃ;ren Tulstrup;publ;President;CEO
Hansa Biopharma AB

¸ - ()-&

Thank you, operator. Good afternoon, and good morning in the U.S. Welcome to the Hansa Biopharma conference call on the results for the first 6 months of 2019. Today, we will review the overall progress and highlights for the second quarter as well as the near-term milestones. Our presentation should take about 15 minutes. And after that, we'll take your questions.

My name is Søren Tulstrup, the CEO of Hansa Biopharma. With me today, I have our new CFO, Donato Spota, who recently joined the company. Also, our Head of Investor Relations, Klaus Sindahl, is with us today.

Please turn to Slide 2. Please allow me to draw your attention to our forward-looking statement, which applies to this presentation.

Please turn to Slide 3.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot